Europe shares dip early; Actelion up on drug results
PARIS, June 16
PARIS, June 16 (Reuters) - European stocks slipped in early trade on Monday, adding to last week's retreat as mounting violence in Iraq prompted investors to further book profits on recent lofty equity market gains.
At 0705 GMT, the FTSEurofirst 300 index of top European shares was down 0.2 percent at 1,386.54 points, further retreating from a 6-1/2 year high hit last week.
On Sunday, Sunni insurgents in Iraq seized Tal Afar, a mainly ethnic Turkmen city in northwestern Iraq after heavy fighting, solidifying their grip on the north after a lightning offensive that threatens to dismember the country.
Shares in Swiss biotech group Actelion Ltd bucked the trend, surging 14.9 percent after the firm said its experimental heart and lung drug Selexipag met its primary goal in a late-stage study, giving it a potential second big seller to replenish its product pipeline. (Reporting by Blaise Robinson; Editing by Sudip Kar-Gupta)
- U.S. pledges 3,000 troops to fight Ebola; experts say more needed
- Tesla prevails in top Massachusetts court over direct sales
- Russia needs government investment to avoid recession, says former finance minister
- Ukraine ratifies EU deal, offers special status to rebels
- Ahead of independence vote, Britain pledges state funding to Scotland |